Articles related to ADVERSE EVENTS

Although immune therapies, such as immune checkpoint inhibitors (ICIs), have significantly improved cancer outcomes, these therapies can also cause off-target tissue damage and response variability. The host microbiome affects ICI responsiveness and risk of immune-related adverse effects (irAEs), according to numerous lines of evidence. These developments show the possibility to control microbiome elements to improve the success of ICI because the microbiome is manipulable.

HER2-Directed ADCs in Gastric Cancer Several antibody-drug conjugates (ADCs) have recently received approval for use in treating a range of solid cancers. This poses difficulties when handling a variety of adverse treatment-related events, some of which can take practitioners into uncharted area. After viewing this CME activity, medical oncologists, pulmonologists, urologists, pathologists, oncology NPs, PAs, oncology nurses, oncology pharmacists, and other HCPs caring for patients with solid tumors should be able to describe the elements of an antibody-drug conjugate (ADC) that may cause adverse events (AEs), identify AEs that result in treatment interruption or discontinuation, and suggest a strategy for managing the key AEs.

Authors found that in 23.6% of a random sample of 2,809 admissions, there were at least one adverse event. 316 of the 978 adverse events were classified as having a significant or higher severity level, and 222 were deemed to be preventable. In 6.8% of all admissions, an adverse event that could have been avoided happened, and in 1% of those cases, the incident had a serious or higher severity rating. Seven people passed away, one of which was thought to be avoidable. The most frequent adverse events (representing 39.0% of all occurrences) were adverse medication events, which were followed by surgical or other procedural events (30.4%), patient-care events (15.0%), and infections related to medical care (11.9%).

The only effective ways to treat TEC are to stop, delay, or modify your patients’ chemotherapy dose. Supportive medications, such as topical keratolytics, wound care, and high-potency topical corticosteroids, respond differently. These medications cause a 2- to 4-week recovery period following the interruption of chemotherapy, which is a somewhat gradual improvement.

In this cohort study of insurance data over an 18-year period covering more than 15,000 pregnancies that involved methadone or buprenoprine use, buprenorphine in pregnancy was associated with a lower risk of adverse neonatal outcomes versus methadone use. However, the risk of adverse maternal outcomes was similar.

Eighty-eight children ages 6 through 12 were randomized to daily pine bark extract, methylphenidate, or placebo for 10 weeks. Total ADHD-Rating Scales scores decreased 29% with pine bark extract, 45% with methylphenidate, and 5% with placebo. Hyperactivity/impulsivity decreased 34% with pine bark extract and 36% with methylphenidate and increased 1% with placebo. Inattention decreased 25% with pine bark extract, 52% with methylphenidate, 9% with placebo. Adverse events were reported 5 times more frequently with methylphenidate than with pine bark.